Skip Navigation

Masks Strongly Recommended but Not Required in Maryland, Starting Immediately

Due to the downward trend in respiratory viruses in Maryland, masking is no longer required but remains strongly recommended in Johns Hopkins Medicine clinical locations in Maryland. Read more.

Brady Urological Institute

Shawn Lupold Laboratory

The Lupold Laboratory is a basic and translational research laboratory focused on the molecular biology of prostate cancer. Our mission is to define the molecular mechanisms that contribute to lethal prostate cancer for the development of new diagnostic, prognostic and therapeutic strategies.

Our research areas of interest include major interests include microRNAs, RNA therapeutics and high-throughput screening approaches.

Research Publications

See PubMed for a complete list of publications featuring the Shawn Lupold Laboratory

View publications

Our Team

The Shawn Lupold Laboratory is a highly collaborative group. Our team values multidisciplinary interactions and projects.

Laboratory Director

Shawn Lupold, Ph.D., is professor of urology and oncology at the Johns Hopkins School of Medicine and co-director of the Prostate Cancer Group for the Sidney Kimmel Comprehensive Cancer Center.

Lab Members

Polina Sysa-Shah, Ph.D., Sr. Research Specialist
Alok Mishra, Ph.D., Research Associate
Akira Kurozumi, M.D., Ph.D., Postdoctoral Fellow
Shireen Chikara, Ph.D., Postdoctoral Fellow

Previous Lab Members

Undergraduate and Summer Students

Luzia Brandner
Brian Mears
Salar Khaleghzadegan
Cara Lang
Ying LI
Ross Liao

Graduate Students

Mark Castanares, Ph.D.
Thiago Martin, Ph.D.

Post-doctoral Fellows

Binod Kumar, Ph.D.
Kenji Zennami, M.D., Ph.D.
Koji Hatano, M.D., Ph.D.
Amarnath Mukherjee, Ph.D.
Xiaohua Ni, Ph.D.
Fatema Rafiqi, Ph.D.
Judit Ribas, Ph.D.
Ping Wu, M.D., Ph.D.

News and UpdatesAndrogen Signaling Regulates the PDCD4 Tumor Suppressor Gene

In the February 2019 issue of Molecular Cancer Research, Kenji Zennami reports that androgen receptor signaling leads to the suppression of PDCD4 mRNA and protein expression through the induction of miR-21 expression. In cell and tumor models of prostate cancer, Kenji found PDCD4 knockdown to enhance cell proliferation, reduce apoptosis, augment tumorigenesis and drive castration resistance. He also found, through collaboration with Luigi Marchionni, that high Gleason grade prostate cancers exhibit low levels of PDCD4 mRNA and high levels of miR-21.

Read about it in Molecular Cancer Research

Collaborators

Our team works closely with laboratories and investigators across Johns Hopkins Medicine to foster discovery. Learn more about our collaborative work and the researchers we’ve teamed up with to tackle prostate cancer.

Collaborators & Laboratories

Other Facilities & Sites